Main Content
Emergency vaccines – Alphavirus Replicons
The aim of this project is to develop and characterise an easily scalable RNA-based vaccine platform that can be rapidly used against highly pathogenic and emerging viruses. In collaboration with BioNTech RNA Pharmaceuticals GmbH, self-amplifying RNAs (saRNAs) are tested as vaccine candidates against e.g. Ebolavirus in animal models. Following the characterisation and optimisation of the immunogenicity of the vaccine candidates, their efficacy is tested. This is done in collaboration with the Animal Facility of the High Security Laboratory (BSL-4 Laboratory) of Philipps University Marburg within the research area Emerging Infections of the German Center for Infection Research (DZIF).
Project Lead
Verena Krähling
Staff members:
Dirk Becker, Alexandra Kupke, Jolanda Mezzacapo, BSL-4 Animal Facility
Project Partners:
Funding:
